{"id":19482,"date":"2022-02-08T10:31:14","date_gmt":"2022-02-08T15:31:14","guid":{"rendered":"https:\/\/medicarereport.org\/?p=19482"},"modified":"2022-02-08T10:31:15","modified_gmt":"2022-02-08T15:31:15","slug":"why-remdesivir-a-highly-effective-covid-treatment-is-a-last-resort-for-providers","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=19482","title":{"rendered":"Why remdesivir, a highly effective COVID treatment, is a last resort for providers"},"content":{"rendered":"\n<p>(By Pien Huang for NPR)<\/p>\n\n\n\n<p>In late December, as the omicron variant surged, the roster of early COVID-19 treatments was looking slim. Newly authorized pills for COVID-19 were in short supply. Several monoclonal antibody drugs didn&#8217;t seem to work.  Continue reading <a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2022\/02\/07\/1078012530\/why-remdesivir-a-highly-effective-treatment-is-a-last-resort-for-providers\" data-type=\"URL\" data-id=\"https:\/\/www.npr.org\/sections\/health-shots\/2022\/02\/07\/1078012530\/why-remdesivir-a-highly-effective-treatment-is-a-last-resort-for-providers\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"72\" class=\"wp-image-3902\" style=\"width: 200px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n\n\n\n<pre class=\"wp-block-preformatted\"><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Pien Huang for NPR) In late December, as the omicron variant surged, the roster of early COVID-19 treatments was<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[52,15],"tags":[],"class_list":["post-19482","post","type-post","status-publish","format-standard","hentry","category-pandemic","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19482"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19482\/revisions"}],"predecessor-version":[{"id":19483,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19482\/revisions\/19483"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}